$134.25
00.00%
Pre-Market: 4:56 PM EDT
15 minutes delayed
Inspire Medical Systems
INSPNYSE
Inspire Medical Systems (NYSE:INSP) Stock, Analyst Ratings, Price Targets, Predictions
Inspire Medical Systems Inc has a consensus price target of $251.71, established from looking at the 66 latest analyst ratings. The last 3 analyst ratings were released from Stifel, B of A Securities, and Piper Sandler on June 24, 2024, June 3, 2024, and May 8, 2024. With an average price target of $203.33 between Stifel, B of A Securities, and Piper Sandler, there's an implied 51.46% upside for Inspire Medical Systems Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
B of A Securities
Piper Sandler
RBC Capital
Mizuho
1calculated from analyst ratings
Analyst Ratings for Inspire Medical Systems
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/24/2024 | Buy Now | 26.63% | Stifel | Jonathan Block | $210 → $170 | Maintains | Hold | Get Alert |
| 06/03/2024 | Buy Now | 37.8% | B of A Securities | Bob Hopkins | $225 → $185 | Maintains | Neutral | Get Alert |
| 05/08/2024 | Buy Now | 89.94% | Piper Sandler | Adam Maeder | $250 → $255 | Maintains | Overweight | Get Alert |
| 04/19/2024 | Buy Now | 112.29% | RBC Capital | Shagun Singh | → $285 | Initiates | → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 86.22% | Mizuho | Anthony Petrone | $250 → $250 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 108.57% | Truist Securities | Richard Newitter | → $280 | Reiterates | Buy → Buy | Get Alert |
| 03/19/2024 | Buy Now | 86.22% | Morgan Stanley | Kallum Titchmarsh | → $250 | Initiates | → Overweight | Get Alert |
| 02/07/2024 | Buy Now | 108.57% | Truist Securities | Richard Newitter | $265 → $280 | Maintains | Buy | Get Alert |
| 02/07/2024 | Buy Now | 86.22% | Mizuho | Anthony Petrone | $225 → $250 | Maintains | Buy | Get Alert |
| 02/06/2024 | Buy Now | 107.08% | Keybanc | Brett Fishbin | → $278 | Initiates | → Overweight | Get Alert |
| 01/19/2024 | Buy Now | 82.5% | Jefferies | — | → $245 | Initiates | → Buy | Get Alert |
| 01/02/2024 | Buy Now | 56.42% | Stifel | Jonathan Block | → $210 | Downgrade | Buy → Hold | Get Alert |
| 12/22/2023 | Buy Now | 93.67% | Truist Securities | Richard Newitter | $240 → $260 | Maintains | Buy | Get Alert |
| 12/13/2023 | Buy Now | 39.29% | Wells Fargo | Larry Biegelsen | → $187 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/08/2023 | Buy Now | 56.42% | Stifel | Jonathan Block | $250 → $210 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 60.15% | Mizuho | Anthony Petrone | $300 → $215 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 78.77% | Truist Securities | Richard Newitter | $260 → $240 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | 82.5% | Wells Fargo | Larry Biegelsen | $330 → $245 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | 86.22% | Stifel | Jonathan Block | $350 → $250 | Maintains | Buy | Get Alert |
| 10/17/2023 | Buy Now | 34.82% | JP Morgan | Robbie Marcus | $340 → $181 | Maintains | Overweight | Get Alert |
| 10/16/2023 | Buy Now | 18.44% | Leerink Partners | Mike Kratky | → $159 | Initiates | → Market Perform | Get Alert |
| 10/02/2023 | Buy Now | 153.26% | Truist Securities | Richard Newitter | → $340 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | Buy Now | 139.85% | UBS | Danielle Antalffy | $405 → $322 | Maintains | Buy | Get Alert |
| 08/24/2023 | Buy Now | 153.26% | Truist Securities | Richard Newitter | $363 → $340 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 153.26% | JP Morgan | Robbie Marcus | $300 → $340 | Maintains | Overweight | Get Alert |
| 08/02/2023 | Buy Now | 160.71% | Lake Street | Frank Takkinen | $305 → $350 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 170.39% | Truist Securities | Richard Newitter | $380 → $363 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 145.81% | Wells Fargo | Larry Biegelsen | $315 → $330 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | 183.05% | Truist Securities | Richard Newitter | $360 → $380 | Maintains | Buy | Get Alert |
| 07/19/2023 | Buy Now | 176.35% | Baird | Mike Polark | → $371 | Initiates | → Outperform | Get Alert |
| 07/13/2023 | Buy Now | 160.71% | Stifel | Jonathan Block | $300 → $350 | Maintains | Buy | Get Alert |
| 07/05/2023 | Buy Now | 164.43% | B of A Securities | Bob Hopkins | $310 → $355 | Maintains | Buy | Get Alert |
| 06/12/2023 | Buy Now | 123.46% | Mizuho | Anthony Petrone | → $300 | Reiterates | Buy → Buy | Get Alert |
| 06/08/2023 | Buy Now | 153.26% | Piper Sandler | Adam Mizrahi | $315 → $340 | Maintains | Overweight | Get Alert |
| 06/08/2023 | Buy Now | 149.53% | Keybanc | Matthew Mishan | $321 → $335 | Maintains | Overweight | Get Alert |
| 05/18/2023 | Buy Now | 168.16% | Piper Sandler | Adam Mizrahi | $335 → $360 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | 126.44% | UBS | Danielle Antalffy | $300 → $304 | Maintains | Buy | Get Alert |
| 05/03/2023 | Buy Now | 134.64% | Piper Sandler | Adam Mizrahi | $305 → $315 | Maintains | Overweight | Get Alert |
| 05/03/2023 | Buy Now | 139.11% | Keybanc | Matthew Mishan | $303 → $321 | Maintains | Overweight | Get Alert |
| 04/14/2023 | Buy Now | 123.46% | Mizuho | Anthony Petrone | → $300 | Initiates | → Buy | Get Alert |
| 04/13/2023 | Buy Now | 123.46% | Mizuho | Anthony Petrone | → $300 | Initiates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 123.46% | Stifel | Jonathan Block | $290 → $300 | Maintains | Buy | Get Alert |
| 03/29/2023 | Buy Now | 123.46% | UBS | Danielle Antalffy | → $300 | Initiates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | 145.81% | Truist Securities | Richard Newitter | $310 → $330 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | 123.46% | JP Morgan | Robbie Marcus | $271 → $300 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | 127.19% | Piper Sandler | Adam Maeder | $300 → $305 | Maintains | Overweight | Get Alert |
| 01/31/2023 | Buy Now | 130.91% | Truist Securities | Richard Newitter | $308 → $310 | Maintains | Buy | Get Alert |
| 01/26/2023 | Buy Now | 123.46% | Piper Sandler | Adam Maeder | $285 → $300 | Maintains | Overweight | Get Alert |
| 01/13/2023 | Buy Now | 125.7% | Keybanc | Matthew Mishan | $287 → $303 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 129.42% | Truist Securities | Richard Newitter | $270 → $308 | Maintains | Buy | Get Alert |
| 12/13/2022 | Buy Now | — | Goldman Sachs | Amit Hazan | — | Upgrade | Neutral → Buy | Get Alert |
| 12/13/2022 | Buy Now | 113.78% | Keybanc | Matthew Mishan | → $287 | Initiates | → Overweight | Get Alert |
| 10/17/2022 | Buy Now | 78.77% | Truist Securities | Richard Newitter | $280 → $240 | Maintains | Buy | Get Alert |
| 08/03/2022 | Buy Now | 112.29% | Piper Sandler | Adam Maeder | $310 → $285 | Maintains | Overweight | Get Alert |
| 06/10/2022 | Buy Now | 86.22% | Truist Securities | Richard Newitter | $296 → $250 | Maintains | Buy | Get Alert |
| 04/13/2022 | Buy Now | 134.64% | Truist Securities | Richard Newitter | → $315 | Initiates | → Buy | Get Alert |
| 04/06/2022 | Buy Now | 101.12% | Wolfe Research | Mike Polark | → $270 | Initiates | → Peer Perform | Get Alert |
| 02/09/2022 | Buy Now | 103.35% | SVB Leerink | Danielle Antalffy | $270 → $273 | Maintains | Outperform | Get Alert |
| 11/03/2021 | Buy Now | 127.19% | Piper Sandler | Adam Maeder | — | Maintains | Overweight | Get Alert |
| 11/03/2021 | Buy Now | 127.19% | Wells Fargo | Larry Biegelsen | — | Maintains | Overweight | Get Alert |
| 11/03/2021 | Buy Now | 142.09% | SVB Leerink | Danielle Antalffy | — | Maintains | Outperform | Get Alert |
| 09/24/2021 | Buy Now | 123.46% | SVB Leerink | Richard Newitter | — | Maintains | Outperform | Get Alert |
| 08/04/2021 | Buy Now | 77.28% | Piper Sandler | Adam Maeder | — | Maintains | Overweight | Get Alert |
| 08/04/2021 | Buy Now | 97.39% | SVB Leerink | Richard Newitter | — | Maintains | Outperform | Get Alert |
| 07/20/2021 | Buy Now | 60.15% | Piper Sandler | Adam Maeder | — | Maintains | Overweight | Get Alert |
| 07/14/2021 | Buy Now | 75.05% | Piper Sandler | Adam Maeder | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Inspire Medical Systems (INSP) stock?
The latest price target for Inspire Medical Systems (NYSE:INSP) was reported by Stifel on June 24, 2024. The analyst firm set a price target for $170.00 expecting INSP to rise to within 12 months (a possible 26.63% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inspire Medical Systems (INSP)?
The latest analyst rating for Inspire Medical Systems (NYSE:INSP) was provided by Stifel, and Inspire Medical Systems maintained their hold rating.
When was the last upgrade for Inspire Medical Systems (INSP)?
The last upgrade for Inspire Medical Systems Inc happened on December 13, 2022 when Goldman Sachs raised their price target to N/A. Goldman Sachs previously had a neutral for Inspire Medical Systems Inc.
When was the last downgrade for Inspire Medical Systems (INSP)?
The last downgrade for Inspire Medical Systems Inc happened on January 2, 2024 when Stifel changed their price target from N/A to $210 for Inspire Medical Systems Inc.
When is the next analyst rating going to be posted or updated for Inspire Medical Systems (INSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inspire Medical Systems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inspire Medical Systems was filed on June 24, 2024 so you should expect the next rating to be made available sometime around June 24, 2025.
Is the Analyst Rating Inspire Medical Systems (INSP) correct?
While ratings are subjective and will change, the latest Inspire Medical Systems (INSP) rating was a maintained with a price target of $210.00 to $170.00. The current price Inspire Medical Systems (INSP) is trading at is $134.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.